{"Clinical Trial ID": "NCT01869764", "Intervention": ["INTERVENTION 1:", "Weapons I (Omega-3 fatty acid)", "Patients receive omega-3 PO daily for 7 to 14 days.", "omega-3 fatty acid: see PO", "Analysis of laboratory biomarkers: related studies", "INTERVENTION 2:", "Army II (Placebo)", "Patients receive placebo PO daily for 7-14 days.", "placebo: given to PO", "Analysis of laboratory biomarkers: related studies"], "Eligibility": ["Incorporation criteria:", "New stage of diagnosis I to III breast cancer and in situ carcinoma (including lobular carcinoma in situ (LCIS) and canalal carcinoma in situ (CDIS))", "- Breast surgery (lumpectomy or mastectomy) is scheduled for at least 7 days from the day of registration.", "\u2022 Ability to understand and sign an informed consent document approved by the Institutional Review Board (IRB)", "Tumours measure at least 1 centimeter on imaging or physical examination", "- Exclusion criteria:", "Any patient with scheduled surgery < 7 days after biopsy", "Patients who are unable to forbear from using NSAIDs or NSAIDs containing acetylsalicylic acid (ASA) at full dose while taking the study drug", "Patients who receive neoadjuvant chemotherapy are not eligible", "Patients currently taking omega-3 fatty acids as they cannot be randomised to placebo", "Patients who have already taken omega-3 fatty acid in the month prior to the study", "Patients with known allergy or hypersensitivity to fish"], "Results": ["Performance measures:", "UFA levels in normal and metastatic breast tissue", "Covariance analysis (ANCOVA) will be used to evaluate the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Covariance analysis (ANCOVA) will be used to evaluate the effect of omega-3 in plasma and red blood cells (RBCs), where the base levels of PUFAs will be included as covariates. PUFA levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3", "Delay: At the time of surgery", "Results 1:", "Title of arm/group: Arm I (Omega-3 fatty acid)", "Description of the arm/group: Patients receive omega-3 PO fatty acid daily for 7 to 14 days.", "omega-3 fatty acid: see PO", "Analysis of laboratory biomarkers: related studies", "Total number of participants analysed: 22", "Average (standard deviation)", "Unit of measurement: ug/ml Normal breast tissue 18:2 n-6: 22 participants", "- 60,986 (40,392)", "18:3 n-3: 22 participants", "3.232 (2.289)", "20:2 n-6: 22 participants", "1.104 (0.96)", "20:4 n-6: 22 participants", "2.221 (1.349)", "20:3 n-3: 22 participants", "0.049 (0.107)", "Normal breast textile 20:5 n-3: 22 participants", "- 0.027 (0.128)", "Normal breast disorders 22:6 n-3: 22 participants", "0.095 (0.443)", "Normal textile n-3: 22 participants", "3.402 (2.572)", "Normal textile n-6: 22 participants", "3.421 (2.085)", "Normal rate of breast tissue n3/n-6: 21 participants", "- 0.948 (0.468)", "18:2 n-6: 22 participants", "44.137 (44.544)", "18:3 n-3: 22 participants", "\u00b7 1.943 (2.162)", "20:2 n-6: 22 participants", "- 0.889 (0.886)", "20:4 n-6: 22 participants", "- 3.208 (1.948)", "20:3 n-3: 22 participants", "0.034 (0.087)", "20:5 n-3: 22 participants", "0.2 (0.665)", "22:6 n-3: 22 participants", "0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0", "N-3 malignant maize: 22 participants", "2.178 (2.41)", "N-6 malignant maize: 22 participants", "48.233 (46.105)", "N-3/n-6 malignant breast rate: 22 participants", "0.029 (0.031)", "\u2022 Differences in PUFA 18:2 n-6: 22 participants", "-16.85 (51.043)", "\u2022 Differences in PUFA 18:3 n-3: 22 participants", "-1,289 (2.784)", "Differences in the level of PUFA 20:2 n-6: 22 participants", "-0.215 (0.866)", "Differences in PUFA level 20:4 n-6: 22 participants", "- 0.986 (1.595)", "Differences in PUFA level 20:3 n-3: 22 participants", "-0.015 (0.105)", "Differences in PUFA level 20:5 n-3: 22 participants", "- 0.173 (0.545)", "Differences in PUFA 22:6 n-3: 22 participants", "-0.095 (0.443)", "\u2022 Difference in PUFA n-3: 22 participants", "-1,224 (2.794)", "Difference in PUFA level in n-6: 22 participants", "- 44,812 (45,463)", "Difference in ratio n-3/n-6: 21 participants", "-0.92 (0.45)", "Results 2:", "Title of arm/group: Arm II (Placebo)", "Description of the arm/group: Patients receive placebo PO daily for 7-14 days.", "placebo: given to PO", "Analysis of laboratory biomarkers: related studies", "Total number of participants analysed: 19", "Average (standard deviation)", "Unit of measurement: ug/ml Normal breast tissue 18:2 n-6: 19 participants", "- 72,762 (50,742)", "18:3 n-3: 19 participants", "- 3,505 (2,041)", "20:2 n-6: 19 participants", "1.008 (0.724)", "20:4 n-6: 19 participants", "\u00b7 2,342 (1.445)", "Normal breast textile 20:3 n-3: 19 participants", "0.038 (0.085)", "Normal breast textile 20:5 n-3: 19 participants", "0.034 (0.147)", "Normal breast disorders 22:6 n-3: 19 participants", "0.061 (0.264)", "Normal breast tissue n-3: 19 participants", "3.64 (2.24)", "Normal breast tissue n-6: 19 participants", "3.413 (1.962)", "Normal rate of breast tissue n3/n-6: 19 participants", "1102 (0.438)", "18:2 n-6: 19 participants", "33 735 (31.548)", "18:3 n-3: 19 participants", "\u00b7 1.356 (1.465)", "20:2 n-6: 19 participants", "- 0.601 (0.657)", "20:4 n-6: 19 participants", "2.248 (1.744)", "20:3 n-3: 19 participants", "0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0", "20:5 n-3: 19 participants", "0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0", "22:6 n-3: 19 participants", "0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0", "N-3 malignant maize: 19 participants", "1.357 (1.466)", "N-6: 19 participants", "36.586 (32.856)", "N-3/n-6 malignant rate: 19 participants", "0.032 (0.016)", "\u2022 Differences in PUFA 18:2 n-6: 19 participants", "-39,027 (38,697)", "\u2022 Differences in PUFA 18:3 n-3: 19 participants", "-2.149 (1.935)", "Differences in the level of PUFA 20:2 n-6: 19 participants", "-0.407 (0.514)", "Differences in the level of PUFA 20:4 n-6: 19 participants", "-0.094 (1.589)", "Differences in the level of PUFA 20:3 n-3: 19 participants", "-0.038 (0.085)", "Differences in the level of PUFA 20:5 n-3: 19 participants", "-0.034 (0.147)", "Differences in PUFA 22:6 n-3: 19 participants", "-0.061 (0.264)", "\u2022 Difference in PUFA n-3: 19 participants", "-2.282 (2.127)", "Difference in PUFA level in n-6: 19 participants", "33.173 (31.836)", "Difference in ratio n-3/n-6: 19 participants", "-1.07 (0.438)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/28 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}